secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2022-10-04T23:59:59+00:00
Accession:  0001628280-22-025942
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci appoints Andreas Busch as Chief Innovation Officer; CTO Matthew Weinstock transitions to consultant
--------------------------------------------------------------------------------

- Andreas Busch resigns from Board on Sept 30 to become Chief Innovation Officer effective Oct 4, 2022.
- Former CTO Matthew Weinstock to serve as consultant after Oct 4; receives 12-month base salary severance, COBRA reimbursement, and $145,125 prorated bonus.
- Dr. Busch brings R&D expertise from Sanofi, Bayer, Shire; led over 10 drugs to FDA approval.
- As Chief Innovation Officer, Dr. Busch will lead R&D, technical operations, and internal/partner programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/0001628280-22-025942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828022025942/absc-20220930.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer